Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.

Ther Adv Med Oncol · 2020 · PMC6987485 · PMID 32064003

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

The combination of afatinib and dasatinib showed a trend towards decreased tumour volume relative to all other treatment arms, approaching statistical significance ( p = 0.06) ( Figure 5A ) at the end of the experiment.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.